This interaction suggests that drugs designed to target GSTP1 might inhibit androgen synthesis or boost the efficacy of other drugs, such as 5-fluorouracil, in inhibiting DNA synthesis for the treatment of prostate cancer. Here, GSTP1 is linked to prostate carcinoma.